Abstract
Aim: We previously found that low-dose X-ray treatment after systemic administration of acridine orange (AO), which is known to have a low toxicity in animals, inhibited tumor growth in experimental studies using mouse osteosarcoma. In this pilot study, we planned to verify the toxicity of intravenous injection of low-dose AO in humans and investigate the anticancer effect of radiation after systemic AO administration (iAOR) for human cancer. Patients and Methods: Eight patients with terminal cancer were treated with iAOR. Results: None of the patients exhibited an adverse effect from AO injection. Three out of the five patients who received a full course of iAOR exhibited clinical or image-based responses, whereas two patients did not. Conclusion: The systemic administration of AO was confirmed not to be toxic in humans, and iAOR was suggested to be potentially effective against radioresistant cancer.
Original language | English |
---|---|
Pages (from-to) | 481-489 |
Number of pages | 9 |
Journal | Anticancer Research |
Volume | 38 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 1 2018 |
Keywords
- Acridine orange
- Autophagy
- Cancer
- Radiotherapy
- Toxicity
ASJC Scopus subject areas
- Oncology
- Cancer Research